CLL Treatment Decisions: Partnering with Your Healthcare Team

CLL management is highly individualized. Effective partnership with your hematologist ensures therapy aligns with your biology, preferences, and life context.

When Treatment Is Indicated (iwCLL Criteria)

  • Symptomatic: B-symptoms (fever, night sweats, weight loss), fatigue interfering with function.
  • Progressive: Bulky nodes/spleen, cytopenias (Hb <10, Plt <100k) from marrow infiltration.
  • Rapid lymphocyte doubling time (<12 mo) — supportive, not sole criterion.

Current First-Line Options (2024)

RegimenBest ForDurationKey Toxicities
BTKi (Acalabrutinib, Zanubrutinib preferred over Ibrutinib)Most; del17p/TP53mutContinuousAtrial fibrillation, bleeding, HTN, arthralgia, diarrhea
Venetoclax + Obinutuzumab (Ven-O)Fit patients; desire time-limited12 cycles (fixed)TLS (ramp-up), neutropenia, infections
Chemoimmunotherapy (FCR/BR)Rare: young, IGHV-mutated, no del17p/TP53mut6 cyclesMyelosuppression, secondary AML, infections

Questions to Ask Your Doctor

  • What are my FISH/TP53/IGHV results? How do they guide choice?
  • Am I a candidate for time-limited Ven-O vs. continuous BTKi?
  • What is the plan for side effect X (e.g., AFib on BTKi)?
  • Are there clinical trials for my profile?
  • How will we monitor (lymphocytes, nodes, MRD)?
  • What happens at progression? (BTKi → Ven-O; Ven-O → BTKi/PI3Ki/clinical trial)

Ongoing Care

  • Infection prevention: IVIG if hypogammaglobulinemia + recurrent infections; non-live vaccines.
  • Skin surveillance (↑ NMSC, melanoma).
  • Richter's transformation surveillance (PET-CT if nodes grow rapidly, B-symptoms).

Medical Conditions - Related Articles